Why BioNTech (BNTX) Shares Are Trading Lower Today - BioNTech (NASDAQ:BNTX)

BioNTech SE BNTX has reported Q2 FY22 revenues of €3.19 billion, down from €5.3 billion a year ago and €6.37 billion in Q1 FY22.
BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and leading to fluctuations in quarterly revenues.
This revenue fluctuation caused by the re-phasing of orders is expected to remain over the rest of the financial year with uptake in demand in key markets in Q4 FY22 related to the Omicron-adapted bivalent vaccine, subject to regulatory approval.
Related: EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters.
EPS of €6.45 ($6.872) missed the consensus of $7.36.
The company and its partner Pfizer Inc PFE signed an agreement with the U.S. government to provide additional 105 million doses of COVID-19 vaccine with an option for another 195 million doses.
BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of omicron in August.
Outlook: BioNTech reaffirms FY22 COVID-19 vaccine revenues of €13 billion - €17 billion as the doses scheduled for delivery in June through August will now be delivered in September through to Q4 FY22.
BioNTech has started manufacturing bivalent Omicron BA.1- and BA.4/5-adapted vaccines and expects to be able to start delivering shots targeted at BA.4 and BA.5 as early as October if it receives regulatory approval.
Price Action: BNTX shares are down 4.98% at $173.99 during the premarket session on the last check Monday.
Photo by x3 from Pixabay

Market News and Data brought to you by Benzinga APIs

BioNTech Earnings Shocker: Posts Lower Than Expected Q2 Profits, Revenues Fall

Comments

Earnings Calendar

Never Miss Important Catalysts

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga